Vertex Pharmaceuticals’ Post

View organization page for Vertex Pharmaceuticals, graphic

356,947 followers

5mo

Today, the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for our CRISPR/Cas9 gene-edited treatment for #SickleCellDisease and #BetaThalassemia; an important step towards bringing this treatment to patients in the European Union. Learn more: https://www.vrtx.com/

6 Comments

Andy Donovan

Sales professional and agent of connectivity within the life sciences sector.

5mo

cc Life Sciences Ontario

2 Reactions

Ali Erbaş

5mo

Vertex Pharmaceuticals Congrulations.Am I job get in Vertex?

Vasiliki Pelekanou MD PhD

Senior Director-Digital Pathology Leader-Science Fellow/Oncology Precision Medicine at Bayer Pharmaceuticals

5mo

Congrats! So inspiring and impactful for patients in need!

1 Reaction

Valencia Greene Foster

Dynamic Thought Leader Engagement and Strategy Professional with awarding winning experience in field marketing and consultative sales.

5mo

Great news for SCD community!!

1 Reaction

Marisa Rackley BS, MHA, PMP

5mo

👏

See more comments

To view or add a comment, sign in

More Relevant Posts

Evidera

23,652 followers
11mo
Report this post
Learn about the new European Union (EU) health technology assessment (#HTA) regulations commencing in 2025, and how these will impact your advanced therapy medicinal products. » https://bit.ly/3O4OkvM #cellandgenetherapy

Learn about the new EU HTA regulations

https://www.evidera.com
Like Comment
To view or add a comment, sign in
Alessandro Bona

R&D Innovation | Precision Medicine | Drug Development | Ex-vivo Pharmacology | Head Of BD @ Inoviem Scientific
6mo
Report this post
what if we could assess, directly on human native diseased tissues, whether a drug is interacting with its target and at the same time identify the triggered pathway and clinical Mode of Action? Well, Nematic Protein Organisation Technique (NPOT) does exactly this. How? Take a look at the video here👇 https://lnkd.in/dA3HqYJh

The future of drug development is NPOT®

https://www.youtube.com/
Like Comment
To view or add a comment, sign in
BioAgilytix

27,199 followers
6mo Edited
Report this post
Join Scientific Officer Lynn Kamen and Emaan Madany, PhD on November 15th, 2023, for an AAPS eChalk talk, exploring the challenges of evaluating safety and efficacy during development of Advanced Therapy Medicinal Products (ATMPs). This session will focus on the potential for ATMPs to induce immune responses and the various platforms used to evaluate their immunogenicity. Register today to delve deeper into this fascinating topic.https://bit.ly/47kB5xk #drugdevelopment #clinicalresearch #immunogenicity #atmp
Like Comment
To view or add a comment, sign in
Peel Hunt

13,163 followers
10mo
Report this post
Biotech: The Cutting Edge - On a week where many were distracted by the FTSE c2% one-day gain (the 100/250 were on a YTD low) following the better-than-expected US inflation print (3%, the slowest rate in more than 2 years), there was also something, potentially, much more seismic for UK markets: reforms coming down the pipe for UK capital markets. We also spend time looking at messenger RNA (mRNA) and its applications away from vaccines (eg coronavirus), how CRISPR (gene editing) is being touted as the solution to everything, and note other bits going on in the news such as whether the FDA Adcomms will become a thing of the past and Illumina’s record fine for ignoring the EU. Read the full article here: https://lnkd.in/eubVqMxZ #biotech #pharma #healthcare #lifesciences Miles Dixon Edward Sham
Like Comment
To view or add a comment, sign in
Steven Erpelinck

BSc MBA Sr. Business Developer at TNO (Efficient Drug Development) & Chief Commercial Officer (CCO) and co-founder of Peregrion. Supporting Biotech and Pharma companies having DMPK, ADME and Bioavailability challenges
5mo
Report this post
Nice movie on addressing #DMPK #ADME issues via an ex vivo perfused liver platform. Via this innovative platform developed within TNO we can investigate biliary excretion, hepatic metabolism and DDIs. This platform can also be used to investigate target binding (efficacy) of small/large drug candidates (incl. #genetherapy and #geneediting). Same kind of studies can be performed via our ex vivo perfused kidney platform. #TNO #OrganPerfusion #Liver #Kidney #HepaticClearance #RenalClearance #Pharmacokinetics #Innovation #Pharma #Biotech #DrugDiscovery #DrugDevelopment

A machine with organs accelerates drug development | Time setters | TNO

https://www.youtube.com/

1 Comment
Like Comment
To view or add a comment, sign in
Michelle Hamill ACIPD

Leader, Human Resources at Catalent, Clinical Development and Supply
11mo
Report this post
Did you know that the time from development to clinic for biologics drugs could be significantly shortened by adopting a parallel & integrated approach to drug substance development, drug product manufacturing, & clinical supply? View our webinar to learn more from Catalent experts in this area. http://ow.ly/p2Ef50OI4sh

Harnessing Parallel Workstreams to Speed Your Biologic into Phase 1-3 Clinical Trials

catalent.voicestorm.com
Like Comment
To view or add a comment, sign in
Gwen Green

Commercial leader focused on Sales, Development, and Commercial Excellence | Bio/Pharma Services, Life Sciences, Consumer Heath & Biotech, CDMO | Crisis Management | Mentor | Collaborator |
11mo
Report this post
Did you know that the time from development to clinic for biologics drugs could be significantly shortened by adopting a parallel & integrated approach to drug substance development, drug product manufacturing, & clinical supply? View our webinar to learn more from Catalent experts in this area. http://ow.ly/p2Ef50OI4sh

Harnessing Parallel Workstreams to Speed Your Biologic into Phase 1-3 Clinical Trials

catalent.voicestorm.com
Like Comment
To view or add a comment, sign in
Melissa Cairone

Sales Operations Manager at Catalent Pharma Solutions
11mo
Report this post
Did you know that the time from development to clinic for biologics drugs could be significantly shortened by adopting a parallel & integrated approach to drug substance development, drug product manufacturing, & clinical supply? View our webinar to learn more from Catalent experts in this area. http://ow.ly/p2Ef50OI4sh

Harnessing Parallel Workstreams to Speed Your Biologic into Phase 1-3 Clinical Trials

catalent.voicestorm.com
Like Comment
To view or add a comment, sign in
Thomas Templer

Senior Talent Sourcer at Catalent Biologics & Gene Therapy
11mo
Report this post
Did you know that the time from development to clinic for biologics drugs could be significantly shortened by adopting a parallel & integrated approach to drug substance development, drug product manufacturing, & clinical supply? View our webinar to learn more from Catalent experts in this area. http://ow.ly/p2Ef50OI4sh

Harnessing Parallel Workstreams to Speed Your Biologic into Phase 1-3 Clinical Trials

catalent.voicestorm.com
Like Comment
To view or add a comment, sign in
Virginie Le Coent

Head of Scientific Affairs, EMEA - bioMérieux, Pharma Quality Control
3mo
Report this post
👉 The introduction of USP Chapter marks a significant shift in #endotoxin detection, and it's vital for industry professionals to understand how this impacts their processes. 🧠 Explore how recombinant Factor C (#rFC) is not just an alternative, but a future-proof solution ⤵

Discover the Future of Endotoxin Detection with rFC and USP Chapter

biomerieux.com
Like Comment
To view or add a comment, sign in